Premium
Progress and prospects for engineered T cell therapies
Author(s) -
Qasim Waseem,
Thrasher Adrian J.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12981
Subject(s) - chimeric antigen receptor , t cell receptor , antigen , viral vector , receptor , biology , genetic enhancement , immunology , t cell , recombinant dna , virology , gene , immune system , genetics
Summary Proof‐of‐concept studies have demonstrated the therapeutic potential of engineered T cells. Transfer of recombinant antigen‐specific T cell receptors ( TCR ) and chimaeric antigen receptors ( CAR s) against tumour and viral antigens are under investigation by multiple approaches, including viral‐ and nonviral‐mediated gene transfer into both autologous and allogeneic T cell populations. There have been notable successes recently using viral vector‐mediated transfer of CAR s specific for B cell antigens, but also reports of anticipated and unanticipated complications in these and other studies. We review progress in this promising area of cellular therapy, and consider developments in antigen receptor therapies including the application of emerging gene‐editing technologies.